Single-Agent Ibrutinib for Rituximab-Refractory Waldenstr&#xF6;m&apos;s Macroglobulinemia: Final Analysis of the Substudy of the Phase III iNNOVATEᵀᴹ Trial

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Lancet Oncol.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia

doi: 10.1016/

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Myelodysplastic syndromes

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

J Clin Oncol

Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA

doi: 10.1200/JCO.21.00838

LeukemiaLymphoma

Single-Agent Ibrutinib is Effective and Well Tolerated in Treatment-Naïve CLL and R/R MCL^1-4

This healthbook SPECIAL is supported by Janssen-Cilag AG

Lymphoma

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia

N Engl J Med.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia

doi: 10.1056/NEJMoa1802917.

LeukemiaLymphoma

Time for a New Standard: Single Agent Ibrutinib shows Long-Term Efficacy and Safety in Previously Treated MCL and CLL^1-4

This healthbook SPECIAL is supported by Janssen-Cilag AG

Genitourinary Cancer

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

Ann Oncol

Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK, ARTIST 2 investigators.

doi: 10.1016/j.annonc.2020.11.017

Genitourinary Cancer

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

Ann Oncol.

Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, Kang JH, Oh SY, Hwang IG, Ji JH, Shin DB, Yu JI, Kim KM, An JY, Choi MG, Lee JH, Kim S, Hong JY, Park JO, Park YS, Lim HY, Bae JM, Kang WK, ARTIST 2 investigators.

doi: 10.1016/j.annonc.2020.11.017.

Leukemia

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

Lancet Haematol.

Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR, Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.

doi: 10.1016/S2352-3026

Oncology · Hematology

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Substudy of the Phase III iNNOVATE^TM Trial

Related content

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Recent Developments in Metastatic Breast Cancer

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

Single-Agent Ibrutinib is Effective and Well Tolerated in Treatment-Naïve CLL and R/R MCL1-4

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia

Time for a New Standard: Single Agent Ibrutinib shows Long-Term Efficacy and Safety in Previously Treated MCL and CLL1-4

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

Single-Agent Ibrutinib is Effective and Well Tolerated in Treatment-Naïve CLL and R/R MCL^1-4

Time for a New Standard: Single Agent Ibrutinib shows Long-Term Efficacy and Safety in Previously Treated MCL and CLL^1-4